Selected research
Industry Research
Xerostomia (Dry Mouth) Therapeutics Industry Research Report 2026
Market perspective
The global Xerostomia (Dry Mouth) Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Xerostomia (Dry Mouth) Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Xerostomia (Dry Mouth) Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Xerostomia (Dry Mouth) Therapeutics include Acacia Pharma, Church & Dwight, Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., OraCoat, Parnell Pharmaceuticals, Inc., Pendopharm and GlaxoSmithKline plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Xerostomia (Dry Mouth) Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (W Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Xerostomia (Dry Mouth) Therapeutics Market by Company
Acacia Pharma
Church & Dwight, Inc.
Colgate-Palmolive Company
Hikma Pharmaceuticals PLC
Lupin Pharmaceuticals, Inc.
OraCoat
Parnell Pharmaceuticals, Inc.
Pendopharm
GlaxoSmithKline plc
Pfizer, Inc.
Sun Pharmaceuticals Industries Ltd.
Xerostomia (Dry Mouth) Therapeutics Segment by Type
Salivary Stimulants
Salivary Substitutes
Dentifrices
Xerostomia (Dry Mouth) Therapeutics Segment by Application
OTC
Prescription
Xerostomia (Dry Mouth) Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Xerostomia (Dry Mouth) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Xerostomia (Dry Mouth) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Xerostomia (Dry Mouth) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Xerostomia (Dry Mouth) Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Xerostomia (Dry Mouth) Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Xerostomia (Dry Mouth) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Salivary Stimulants
- Salivary Substitutes
- Dentifrices
Applications
- OTC
- Prescription
Companies covered
- Acacia Pharma
- Church & Dwight, Inc.
- Colgate-Palmolive Company
- Hikma Pharmaceuticals PLC
- Lupin Pharmaceuticals, Inc.
- OraCoat
- Parnell Pharmaceuticals, Inc.
- Pendopharm
- GlaxoSmithKline plc
- Pfizer, Inc.
- Sun Pharmaceuticals Industries Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Xerostomia (Dry Mouth) Therapeutics Market Size (2021-2032)
- 2.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales (2021-2032)
- 2.2.3 Global Xerostomia (Dry Mouth) Therapeutics Market Average Price (2021-2032)
- 2.3 Xerostomia (Dry Mouth) Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Salivary Stimulants
- 2.3.3 Salivary Substitutes
- 2.3.4 Dentifrices
- 2.4 Xerostomia (Dry Mouth) Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 OTC
- 2.4.3 Prescription
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Xerostomia (Dry Mouth) Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Xerostomia (Dry Mouth) Therapeutics Sales (W Tons) of Manufacturers (2021-2026)
- 3.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Xerostomia (Dry Mouth) Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Xerostomia (Dry Mouth) Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Xerostomia (Dry Mouth) Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Xerostomia (Dry Mouth) Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Xerostomia (Dry Mouth) Therapeutics, Established Date
- 3.9 Global Xerostomia (Dry Mouth) Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Acacia Pharma
- 4.1.1 Acacia Pharma Company Information
- 4.1.2 Acacia Pharma Business Overview
- 4.1.3 Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.1.5 Acacia Pharma Recent Developments
- 4.2 Church & Dwight, Inc.
- 4.2.1 Church & Dwight, Inc. Company Information
- 4.2.2 Church & Dwight, Inc. Business Overview
- 4.2.3 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.2.5 Church & Dwight, Inc. Recent Developments
- 4.3 Colgate-Palmolive Company
- 4.3.1 Colgate-Palmolive Company Company Information
- 4.3.2 Colgate-Palmolive Company Business Overview
- 4.3.3 Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.3.5 Colgate-Palmolive Company Recent Developments
- 4.4 Hikma Pharmaceuticals PLC
- 4.4.1 Hikma Pharmaceuticals PLC Company Information
- 4.4.2 Hikma Pharmaceuticals PLC Business Overview
- 4.4.3 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.4.5 Hikma Pharmaceuticals PLC Recent Developments
- 4.5 Lupin Pharmaceuticals, Inc.
- 4.5.1 Lupin Pharmaceuticals, Inc. Company Information
- 4.5.2 Lupin Pharmaceuticals, Inc. Business Overview
- 4.5.3 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.5.5 Lupin Pharmaceuticals, Inc. Recent Developments
- 4.6 OraCoat
- 4.6.1 OraCoat Company Information
- 4.6.2 OraCoat Business Overview
- 4.6.3 OraCoat Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 OraCoat Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.6.5 OraCoat Recent Developments
- 4.7 Parnell Pharmaceuticals, Inc.
- 4.7.1 Parnell Pharmaceuticals, Inc. Company Information
- 4.7.2 Parnell Pharmaceuticals, Inc. Business Overview
- 4.7.3 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.7.5 Parnell Pharmaceuticals, Inc. Recent Developments
- 4.8 Pendopharm
- 4.8.1 Pendopharm Company Information
- 4.8.2 Pendopharm Business Overview
- 4.8.3 Pendopharm Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pendopharm Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.8.5 Pendopharm Recent Developments
- 4.9 GlaxoSmithKline plc
- 4.9.1 GlaxoSmithKline plc Company Information
- 4.9.2 GlaxoSmithKline plc Business Overview
- 4.9.3 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.9.5 GlaxoSmithKline plc Recent Developments
- 4.10 Pfizer, Inc.
- 4.10.1 Pfizer, Inc. Company Information
- 4.10.2 Pfizer, Inc. Business Overview
- 4.10.3 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.10.5 Pfizer, Inc. Recent Developments
- 4.11 Sun Pharmaceuticals Industries Ltd.
- 4.11.1 Sun Pharmaceuticals Industries Ltd. Company Information
- 4.11.2 Sun Pharmaceuticals Industries Ltd. Business Overview
- 4.11.3 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
- 4.11.5 Sun Pharmaceuticals Industries Ltd. Recent Developments
5 Global Xerostomia (Dry Mouth) Therapeutics Market Scenario by Region
- 5.1 Global Xerostomia (Dry Mouth) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2027-2032
- 5.3 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Xerostomia (Dry Mouth) Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Xerostomia (Dry Mouth) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Xerostomia (Dry Mouth) Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Xerostomia (Dry Mouth) Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Xerostomia (Dry Mouth) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Xerostomia (Dry Mouth) Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Xerostomia (Dry Mouth) Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Xerostomia (Dry Mouth) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Xerostomia (Dry Mouth) Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Xerostomia (Dry Mouth) Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Xerostomia (Dry Mouth) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Xerostomia (Dry Mouth) Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Xerostomia (Dry Mouth) Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Type (2021-2032) & (W Tons)
- 6.1.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Xerostomia (Dry Mouth) Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Application (2021-2032) & (W Tons)
- 7.1.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Xerostomia (Dry Mouth) Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Xerostomia (Dry Mouth) Therapeutics Value Chain Analysis
- 8.1.1 Xerostomia (Dry Mouth) Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Xerostomia (Dry Mouth) Therapeutics Production Mode & Process
- 8.2 Xerostomia (Dry Mouth) Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Xerostomia (Dry Mouth) Therapeutics Distributors
- 8.2.3 Xerostomia (Dry Mouth) Therapeutics Customers
9 Global Xerostomia (Dry Mouth) Therapeutics Analyzing Market Dynamics
- 9.1 Xerostomia (Dry Mouth) Therapeutics Industry Trends
- 9.2 Xerostomia (Dry Mouth) Therapeutics Industry Drivers
- 9.3 Xerostomia (Dry Mouth) Therapeutics Industry Opportunities and Challenges
- 9.4 Xerostomia (Dry Mouth) Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst